NEXGEL, Inc.
NEXGEL, Inc. scores highest on Anchor (47) and lowest on Torque (19). Its PosiPenta is 33.47 out of 100, weaker than most similar companies.
On the Penta Grid this week, NEXGEL, Inc. is Grid #705 of 836 in the Healthcare sector in United States, and Grid #3,405 of 3,999 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| NEXGEL, Inc. | 33.47 | 45 | 36 | 20 | 19 | 47 |
| VivoSim Labs, Inc. | 20.57 | 0 | 16 | 6 | 52 | 29 |
| Silo Pharma, Inc. | 41.29 | 46 | 45 | 14 | 60 | 42 |
| Calidi Biotherapeutics, Inc. | 25.19 | 40 | 40 | 5 | 16 | 25 |
| Decoy Therapeutics Inc. | 47.86 | 92 | 50 | 3 | 46 | 48 |
| Bluejay Diagnostics, Inc. | 37.96 | 48 | 47 | 6 | 53 | 36 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.38 |
| P/B ratio | 0.55 |
EEarnings
| Trailing EPS | ₹-1401.78 |
| Forward EPS | ₹-416.75 |
NNitro
| Price | 529.46 |
| 52-week high | 5398.75 |
| 52-week low | 284.14 |
| Fall from 52-week high | 90.2% |
TTorque
| Return on equity (ROE) | -115.06% |
| Debt-to-equity | 1.36 |
AAnchor
| Beta (price swings) | 0.81 |
| Market cap | ₹25 Cr |
| Insider holding | 14.02% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is NEXGEL, Inc.'s PosiPenta score?
NEXGEL, Inc.'s PosiPenta is 33.47 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does NEXGEL, Inc. stand on the Penta Grid?
On the Penta Grid this week, NEXGEL, Inc. is Grid #705 of 836 in the Healthcare sector in United States, and Grid #3,405 of 3,999 in United States.
Which PosiPenta pillar is strongest for NEXGEL, Inc.?
Anchor (stability and dividends), with a score of 47 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for NEXGEL, Inc.?
Torque (durability), with a score of 19 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.